Results 111 to 117 of about 1,993 (117)

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

European Journal of Nuclear Medicine and Molecular Imaging, 2019
Guido Krenning, Lisa Bodei, Giovanni Paganelli   +2 more
exaly  

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning

European Journal of Nuclear Medicine and Molecular Imaging, 2018
Anna Sarnelli, Lisa Bodei, Marta Cremonesi   +2 more
exaly  

Treatment planning in PRRT based on simulated PET data and a PBPK model

Nuklearmedizin - NuclearMedicine, 2017
Gerhard Glatting, Felix Mottaghy, Deni Hardiansyah   +2 more
exaly  

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

European Journal of Nuclear Medicine and Molecular Imaging, 2015
Guido Krenning, Mark Konijnenberg, Casper van Eijck   +2 more
exaly  

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

Radiotherapy and Oncology, 2012
Anna Sowa-Staszczak, Dariusz Pawlak, Renata Mikolajczak   +2 more
exaly  

A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation

Journal of Clinical Medicine, 2019
Lisa Bodei, Jarosław Ćwikła, Jarosław B Ćwikła   +2 more
exaly  

Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model

Physica Medica, 2017
Gerhard Glatting, Felix Mottaghy, Deni Hardiansyah   +2 more
exaly